BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
With subsequent follow-through days mounting and stocks refusing to give up ground, this rally is showing it might be for real. The post BMRN Stock An Example Of Stock Market Character Change appeared

BioMarin: Priced For Perfection

07:28pm, Tuesday, 31'st Jan 2023
BioMarin has a core cadre of molecules with modestly growing revenues. Its VOXZOGO has clear blockbuster potential.
BioMarin Pharmaceutical Inc. revenues for Q3 of 2022 came in at $505.3 million, which was a year-over-year growth of 24%. It has potential to receive U.S. marketing approval of ROCTAVIAN for the treat

Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?

08:24am, Wednesday, 25'th Jan 2023 Zacks Investment Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
The world of pharmaceutical progress happens incrementally and exponentially. That is, therapies are iteratively improved while breakthrough treatments are also created and discovered.

Investing in Biotech ETFs

04:56pm, Friday, 20'th Jan 2023 The Motley Fool
Here are the five best biotech ETFs to invest in right now.

Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?

11:20am, Monday, 16'th Jan 2023 Zacks Investment Research
Style Box ETF report for SCHM

Cramer Is Holding This Biotech Stock

02:16pm, Thursday, 12'th Jan 2023 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN). When asked about Black Stone Minerals LP (NYSE: BSM), he said, "I like this situat
Wedbush has increased the price target on BioMarin Pharmaceutical Inc (NASDAQ: BMRN) from $74 to $84 while reiterating the Neutral rating. BioMarin reported three-year Phase 3 GENEr8-1 results f

6 Analysts Have This to Say About Biomarin Pharmaceutical

06:00pm, Wednesday, 11'th Jan 2023 Benzinga
Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0

2 Top Biotech Stocks Defying the Bear Market

05:43pm, Tuesday, 10'th Jan 2023 The Motley Fool
Some stocks are hitting new highs.

2 Top Biotech Stocks Defying the Bear Market

12:43pm, Tuesday, 10'th Jan 2023
Some stocks are hitting new highs.
Bank of America Global Research Sr. Pharma Analyst Geoff Meacham joins Yahoo Finance Live anchors Akiko Fujita and Rachelle Akuffo to discuss China's COVID-19 chaos, the pharma space, biotech stocks,

BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA

04:10pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE